Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.
Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, Grammond P, Lugaresi A, Hupperts R, Cristiano E, Van Pesch V, Grand'maison F, La Spitaleri D, Rio ME, Flechter S, Oreja-Guevara C, Giuliani G, Savino A, Amato MP, Petersen T, Fernandez-Bolanos R, Bergamaschi R, Iuliano G, Boz C, Lechner-Scott J, Deri N, Gray O, Verheul F, Fiol M, Barnett M, van Munster E, Santiago V, Moore F, Slee M, Saladino ML, Alroughani R, Shaw C, Kasa K, Petkovska-Boskova T, den Braber-Moerland L, Chapman J, Skromne E, Herbert J, Poehlau D, Needham M, Bacile EA, Arruda WO, Paine M, Singhal B, Vucic S, Cabrera-Gomez JA, Butzkueven H; MSBase Study Group. Kalincik T, et al. Among authors: kasa k. PLoS One. 2013 May 21;8(5):e63480. doi: 10.1371/journal.pone.0063480. Print 2013. PLoS One. 2013. PMID: 23704913 Free PMC article. Clinical Trial.
Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.
Spelman T, Gray O, Trojano M, Petersen T, Izquierdo G, Lugaresi A, Hupperts R, Bergamaschi R, Duquette P, Grammond P, Giuliani G, Boz C, Verheul F, Oreja-Guevara C, Barnett M, Grand'Maison F, Edite Rio M, Lechner-Scott J, Van Pesch V, Fernandez Bolanos R, Flechter S, Den Braber-Moerland L, Iuliano G, Amato MP, Slee M, Cristiano E, Saladino ML, Paine M, Vella N, Kasa K, Deri N, Herbert J, Moore F, Petkovska-Boskova T, Alroughani R, Savino A, Shaw C, Vucic S, Santiago V, Bacile EA, Skromne E, Poehlau D, Cabrera-Gomez JA, Lucas R, Butzkueven H. Spelman T, et al. Among authors: kasa k. Ann Neurol. 2014 Dec;76(6):880-90. doi: 10.1002/ana.24287. Epub 2014 Oct 20. Ann Neurol. 2014. PMID: 25283272
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
Zhou Y, Claflin SB, Stankovich J, van der Mei I, Simpson S Jr, Roxburgh RH, Kalincik T, Blizzard L, Lugaresi A, Alroughani R, Sajedi SA, Butzkueven H, Pucci E, Spitaleri D, Granella F, Cristiano E, Yamout B, Hughes S, Gouider R, Sánchez Menoyo JL, Olascoaga J, McGuigan C, Shaw C, Kermode AG, Kasa K, Al-Harbi T, Altintas A, Laureys G, Fragoso Y, Hardy TA, Csepany T, Sirbu CA, Decoo D, Sas A, Alvarez-Cermeño JC, Kotkata K, Millán-Pascual J, Taylor BV. Zhou Y, et al. Among authors: kasa k. Mult Scler. 2020 Nov;26(13):1765-1774. doi: 10.1177/1352458519881994. Epub 2019 Oct 31. Mult Scler. 2020. PMID: 31668127
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A; MSBase Study Group. Kalincik T, et al. JAMA Neurol. 2023 Jul 1;80(7):702-713. doi: 10.1001/jamaneurol.2023.1184. JAMA Neurol. 2023. PMID: 37437240 Free PMC article.
Prevalence of cognitive impairment among Hungarian patients with relapsing-remitting multiple sclerosis and clinically isolated syndrome.
Sandi D, Biernacki T, Szekeres D, Füvesi J, Kincses ZT, Rózsa C, Mátyás K, Kása K, Matolcsi J, Zboznovits D, Burány Z, Langane É, Vécsei L, Bencsik K. Sandi D, et al. Among authors: kasa k. Mult Scler Relat Disord. 2017 Oct;17:57-62. doi: 10.1016/j.msard.2017.06.017. Epub 2017 Jul 1. Mult Scler Relat Disord. 2017. PMID: 29055476
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ; NAVIGATE ESUS Investigators. Hart RG, et al. N Engl J Med. 2018 Jun 7;378(23):2191-2201. doi: 10.1056/NEJMoa1802686. Epub 2018 May 16. N Engl J Med. 2018. PMID: 29766772 Free article. Clinical Trial.
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R, Ameriso SF, Endres M, Lutsep H, Messé SR, Spence JD, Nedeltechev K, Perera K, Santo G, Olavarria V, Lindgren A, Bangdiwala S, Shoamanesh A, Berkowitz SD, Mundl H, Connolly SJ, Hart RG; NAVIGATE ESUS Investigators. Kasner SE, et al. Lancet Neurol. 2018 Dec;17(12):1053-1060. doi: 10.1016/S1474-4422(18)30319-3. Epub 2018 Sep 28. Lancet Neurol. 2018. PMID: 30274772 Free PMC article. Clinical Trial.
31 results